Selective GABA release as a mechanistic basis of high-frequency stimulation used for the treatment of neuropsychiatric diseases

Sustained-release (+)-PHNO [MK-458 (HPMC

Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation

✍ Dr. Jesse M. Cedarbaum; Mary Clark; Linda H. Toy; Alison Green-Parsons 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 683 KB

## Abstract 4‐‐Propyl‐9‐hydroxynaphthoxazine, or MK‐458 (HPMC), a selective, nonergot D2 agonist administered orally twice a day in sustained‐release form, was studied as adjunctive therapy with carbidopa‐levodopa (Sinemet) in 12 Parkinson's disease patients with motor response fluctuations. The do